Table 3.

Risk of hepatic events according to peak CD4 count among HCV/HIV-coinfected patients.

	Peak CD4 cell count
Characteristics	>500 cells/μL	351–500 cells/μL	200–350 cells/μL	<200 cells/μL	P value for trend
Patients	468	163	102	60	–
Hepatic events	13	7	10	13	–
Person-years	3529	910	492	142	–
Incidence per 1000 PYs (95% CI)	3.7 (1.7–5.7)	7.7 (2.0–13.4)	20.3 (7.9–32.8)	91.5 (44.1–139.0)
Multivariable aOR (95% CI), model 1	1.00 (Ref)	1.57 (0.62–4.01)	3.80 (1.62–8.94)	9.68 (4.24–22.10)	<0.001
P-value of model 1		0.345	0.002	<0.001
Multivariable aOR (95% CI), Model 2	1.00 (Ref)	1.54 (0.60–3.95)	2.92 (1.19–7.13)	7.36 (3.09–17.52)	<0.001
P-value of model 2		0.368	0.019	<0.001
Multivariable aOR (95% CI), Model 3	1.00 (Ref)	1.28 (0.49–3.33)	2.54 (1.01–6.38)	5.50 (2.23–13.60)	<0.001
P-value of model 3		0.619	0.048	<0.001
Multivariable aOR (95% CI), Model 4	1.00 (Ref)	0.98 (0.35–2.74)	2.25 (0.87–5.86)	3.96 (1.51–10.40)	0.004
P-value of model 4		0.974	0.095	0.005

Multivariate logistics regression models, backward Wald method was used. Model 1, Adjusted for age at enrollment and gender (male and female); Model 2, Model 1 plus adjustment for the baseline CD4 cell count and initial antiretroviral regimen (NRTIs plus NNRTIs, NRTIs plus PIs, other regimens/unknown); Model 3, Model 2 plus adjustment for the liver cirrhosis (with and without), platelet, hemoglobin, ALT, albumin, total bilirubin; Model 4, Model 3 plus adjustment for the HBsAg status (positive and negative), HCV RNA, and anti-HCV treatment (with and without).

The CI is determined by assuming that the ratio conforms to the normal distribution.

ALT: Alanine aminotransferase; CI: Confidence interval; HBsAg: Hepatitis B surface antigen; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; NRTIs: Nucleoside reverse transcriptase inhibitors; NNRTIs: Non-nucleoside reverse transcriptase inhibitors; PIs: Protease inhibitors; PYs: Person years; RNA: Ribonucleic acid; –: Not applicable.